@article{0f4c778eabb14de6aa6b4dc1ff11fae7,
title = "Spatially resolved transcriptomics of high-grade serous ovarian carcinoma",
abstract = "Bulk and single-cell RNA sequencing do not provide full characterization of tissue spatial diversity in cancer samples, and currently available in situ techniques (multiplex immunohistochemistry and imaging mass cytometry) allow for only limited analysis of a small number of targets. The current study represents the first comprehensive approach to spatial transcriptomics of high-grade serous ovarian carcinoma using intact tumor tissue. We selected a small cohort of patients with highly annotated high-grade serous ovarian carcinoma, categorized them by response to neoadjuvant chemotherapy (poor or excellent), and analyzed pre-treatment tumor tissue specimens. Our study uncovered extensive differences in tumor composition between the poor responders and excellent responders to chemotherapy, related to cell cluster organization and localization. This in-depth characterization of high-grade serous ovarian carcinoma tumor tissue from poor and excellent responders showed that spatial interactions between cell clusters may influence chemo-responsiveness more than cluster composition alone.",
keywords = "Omics, Oncology, Pathology",
author = "Elaine Stur and Sara Corvigno and Mingchu Xu and Ken Chen and Yukun Tan and Sanghoon Lee and Jinsong Liu and Emily Ricco and Daniel Kraushaar and Patricia Castro and Jianhua Zhang and Sood, {Anil K.}",
note = "Funding Information: We thank E. Goodoff (Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, Texas) for editorial assistance. This research was performed in collaboration with the Pathology and Histology Core, which is supported in part by the P30 Cancer Center Support Grant (NCI-CA125123) and by the Genomic and RNA Profiling Core at Baylor College of Medicine with funding from the NIH S10 grant (1S10OD023469). This research was supported, in part, by the MD Anderson Ovarian Cancer SPORE (P50 CA217685) and grants R35 CA209904 and U01 CA213759, P30 CA016672, the MD Anderson Ovarian Cancer Moon Shot, by the American Cancer Society, the Ovarian Cancer Research Alliance, the Dunwoody Fund, the Gordon Fund, and by the Frank McGraw Memorial Chair in Cancer Research. E.S. is supported by Ovarian Cancer Research Alliance (OCRA number FP00006137). S.C. is funded by the Foundation Amy Krouse Rosenthal Ovarian Cancer Early Detection Research Grant through The Foundation for Women's Cancer 2020/2021 (AWD00005708). Graphical abstract adapted from “New strategies for treating cancer”, by BioRender.com (2022). Retrieved from https://app.biorender.com/biorender-templates, Conceptualization, Methodology, Investigation, Visualization, Writing (Original Draft/Review and Editing): E.S. S.C. Conceptualization, Review and Editing, Supervision, Funding Acquisition and Project Administration: A.K.S. Data collection and curation: E.S. S.C. S.L. E.R. D.K. J.L. and P.C. Formal Analysis, Data Curation, Software: M.X. K.C. and J.Z. Anil K. Sood is a shareholder of BioPath and is a consultant for Merck, Astra Zeneca, GSK, and Kiyatec. The other authors declare no competing interests. Funding Information: We thank E. Goodoff (Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, Texas) for editorial assistance. This research was performed in collaboration with the Pathology and Histology Core, which is supported in part by the P30 Cancer Center Support Grant ( NCI-CA125123 ) and by the Genomic and RNA Profiling Core at Baylor College of Medicine with funding from the NIH S10 grant ( 1S10OD023469 ). This research was supported, in part, by the MD Anderson Ovarian Cancer SPORE ( P50 CA217685 ) and grants R35 CA209904 and U01 CA213759 , P30 CA016672 , the MD Anderson Ovarian Cancer Moon Shot, by the American Cancer Society , the Ovarian Cancer Research Alliance , the Dunwoody Fund, the Gordon Fund, and by the Frank McGraw Memorial Chair in Cancer Research . E.S. is supported by Ovarian Cancer Research Alliance (OCRA number FP00006137 ). S.C. is funded by the Foundation Amy Krouse Rosenthal Ovarian Cancer Early Detection Research Grant through The Foundation for Women{\textquoteright}s Cancer 2020/2021 ( AWD00005708 ). Graphical abstract adapted from “New strategies for treating cancer”, by BioRender.com (2022). Retrieved from https://app.biorender.com/biorender-templates Publisher Copyright: {\textcopyright} 2022 The Author(s)",
year = "2022",
month = mar,
day = "18",
doi = "10.1016/j.isci.2022.103923",
language = "English (US)",
volume = "25",
journal = "iScience",
issn = "2589-0042",
publisher = "Elsevier Inc.",
number = "3",
}